FDA clears generic lenacapavir as UK Casgevy patient finishes treatment

The gene-editing story that moved this week was not a trial readout. It was a hospital press release. On 29 October, Manchester University NHS Foundation Trust said a 15-year-old girl from Cheadle had become the first patient in the UK to finish Casgevy treatment for sickle cell disease at Royal Manchester Children's Hospital.

Casgevy edits a patient's own blood stem cells. NICE approved it for NHS use across England in February 2025, the trust said. The process is not quick. Cells are collected, sent to the Netherlands for editing, and the round trip takes around six months. The recommended starting collection is about 22 million cells. Aisha, the patient, was admitted for two months while her immunity recovered.

That timeline is the point. Gene editing has reached the clinic, but it still behaves like a transplant service, not a pharmacy counter. The trust says around 15,000 people in the UK live with sickle cell disease. It mainly affects Black African and Black Caribbean communities and can cause severe pain, strokes, organ damage and heart failure.

What else the week actually contains

Readers looking for a fresh efficacy number will not find one here. No new gene-editing trial result appeared in the past week. The closest items are older. A STAT report on 2 November said Kymera Therapeutics will release mid-stage data for KT-621 in eczema before the end of the year. The pill targets the immunology market dominated by Dupixent, which has 1.4 million patients on therapy. Jefferies analysts called it "one of the most impactful I&I readouts this year," STAT reported. Visible Alpha forecasts nearly $4 billion in sales by 2035, including more than $3 billion in eczema.

That is a forecast, not a result. The other clinical item is older still. An arXiv paper submitted on 30 October describes a genetic programming method for job-shop scheduling, with no biology in it at all.

The most concrete regulatory news of the week sits next to the gene-editing file rather than inside it. STAT reported on 2 November that the FDA gave tentative approval to Dr Reddy's Laboratories for a generic version of lenacapavir. Gilead markets the injectable HIV prevention drug as Yetzugo. The annual cost per person will be $40, comparable to daily tablets, and the company plans to start shipping next month. STAT's 3 November newsletter repeated the details.

Gene editing and generic manufacturing rarely share a page. This week they do, and the contrast is uncomfortable. One offers a six-month, cell-by-cell procedure for a condition with 15,000 UK patients. The other offers six-monthly protection for $40 a year across dozens of low- and middle-income countries.

Manufacturing is the quiet constraint

The capacity question behind both stories got a partial answer on 3 November. Lonza agreed to buy five US manufacturing sites from Merck KGaA, taking its US site count to nine, according to Reuters as summarised by STAT. The facilities sit in Missouri, Wisconsin, Indiana and California. The deal expands Lonza's ability to produce advanced cancer and gene therapies. Lonza has been assembling this network by acquisition, including Roche's biologics plant in Vacaville, California, in 2024.

Contract manufacturing is where cell and gene therapies either scale or stall. A therapy that needs edited cells shipped to the Netherlands and back depends on exactly this kind of capacity. It also depends on how much of that capacity is booked years ahead.

The other side of the ledger is cost. A new stadium in Milan will carry the Generali name for 20 years at a reported €650 million ($725 million), SportsPro reported on 30 October, against a €1.2 billion ($1.3 billion) build. That is a single sponsorship. It is also roughly the scale at which drug pricing arguments are conducted. It shows how far the $40 lenacapavir figure sits from the rest of the market it will enter.

What to watch

Two dated items matter more than anything published this week. Kymera's KT-621 eczema data are due before the end of the year, and that readout will be judged on efficacy, not on manufacturing. Separately, the UK Casgevy programme now has one completed patient. The trust gave no figure for how many others are in the pipeline, so the rollout's pace remains unknown.

Until then, treat the week's gene-editing news as logistics. A girl rang a bell in Manchester. A generic maker got a tentative approval. A contractor bought five factories. None of it is a cure curve, and all of it decides whether the cures arrive.